(185) An End-to-End High-Throughput Formulation Device Platform for mRNA & LNP Screening

Introduction: LNPs have been widely utilized in prophylactic vaccines and liver directed therapies; however, their applications in other areas remain limited due to challenges in payload design, LNP chemistry, composition, and formulation process optimization. To address these challenges and facilitate clinical translation, promising methodologies, such as barcoded in vivo screening and plate-based in vitro assays, have been adopted but often require labor-intensive, one-by-one formulation of LNPs. Therefore, high-throughput platforms are crucial to accelerating genetic medicine development